Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.
For nearly six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
And as our clients have grown, so has our firm. Wilson Sonsini now represents many of the largest companies in the world—and thousands of the smallest ones, too.
On January 12, aerospace suppliers Woodward, Inc. and Hexcel Corporation announced a definitive agreement to combine in an all-stock merger of equals to create a premier integrated systems provider serving the aerospace and industrial sectors. Wilson Sonsini advised Woodward in the transaction.
On January 13, Visa Inc., the world leader in digital payments, announced it had signed a definitive agreement to acquire Plaid, a San Francisco-based fintech company that enables applications to connect with users’ bank accounts. Visa will pay total purchase consideration of $5.3 billion to acquire Plaid. Once closed, the combination of Visa and Plaid is expected to provide significant benefits to developers, financial institutions and consumers. Wilson Sonsini Goodrich & Rosati is advising Plaid in the transaction.
On December 3, 2019, NanoString Technologies, a leading provider of life science tools for translational research, announced a strategic transaction to exclusively license select nCounter-based diagnostic assets and rights to Veracyte for $50 million in cash and Veracyte stock, plus up to $10 million in cash upon satisfaction of future potential milestones. The transaction closed on December 3, 2019. Wilson Sonsini Goodrich & Rosati represented NanoString in the transaction.
On November 27, 2019, Elevar Therapeutics completed its merger transaction with HLB, a South Korean company whose shares are publicly traded on the Korean stock exchange, pursuant to which Elevar became a wholly-owned subsidiary of HLB. Elevar is a pharmaceutical company based primarily in Utah specializing in clinical development of promising therapies for unmet medical needs in cancer. Wilson Sonsini acts as patent, corporate and technology transactions counsel for Elevar, including in connection with the merger transaction.